Streetbeat News

Analyst Ratings

DKS

DRI

LEVI

Wall Street's most accurate analysts recommend three high-dividend yielding consumer stocks: DICK'S Sporting Goods (DKS), Darden Restaurants (DRI), and Levi Strauss (LEVI). These companies have dividend yields of 3.04%, 3.16%, and 3.62%, respectively.

Portfolio Pulse from Lisa Levin

May 18, 2023 | 1:18 pm

KD

Susquehanna analyst James Friedman maintains a Neutral rating on Kyndryl Holdings (NYSE:KD) and lowers the price target from $17 to $14.

Portfolio Pulse from Benzinga Newsdesk

May 18, 2023 | 1:17 pm

EPR

RBC Capital analyst Michael Carroll has reiterated a Sector Perform rating on EPR Properties (NYSE:EPR) and maintained a $44 price target.

Portfolio Pulse from richadhand@benzinga.com

May 18, 2023 | 1:16 pm

JD

Susquehanna analyst Shyam Patil maintains a Neutral rating on JD.com (NASDAQ:JD) and lowers the price target from $45 to $40.

Portfolio Pulse from Benzinga Newsdesk

May 18, 2023 | 1:16 pm

DT

RBC Capital analyst Matthew Hedberg reiterated an Outperform rating on Dynatrace (NYSE:DT) and maintained a $52 price target.

Portfolio Pulse from richadhand@benzinga.com

May 18, 2023 | 1:16 pm

EW

Truist Securities analyst Richard Newitter maintains a Buy rating on Edwards Lifesciences (NYSE:EW) and raises the price target from $97 to $101.

Portfolio Pulse from Benzinga Newsdesk

May 18, 2023 | 1:16 pm

WIX

RBC Capital analyst Brad Erickson has reiterated an Outperform rating on Wix.com (NASDAQ:WIX) and maintained a $115 price target.

Portfolio Pulse from richadhand@benzinga.com

May 18, 2023 | 1:15 pm

COP

RBC Capital analyst Scott Hanold has reiterated an Outperform rating on ConocoPhillips (NYSE:COP) and maintained a $133 price target.

Portfolio Pulse from richadhand@benzinga.com

May 18, 2023 | 1:14 pm

IART

Truist Securities analyst Richard Newitter maintains a Hold rating on Integra Lifesciences (NASDAQ:IART) and lowers the price target from $58 to $54.

Portfolio Pulse from Benzinga Newsdesk

May 18, 2023 | 1:14 pm

INSP

Piper Sandler analyst Adam Mizrahi maintains an Overweight rating on Inspire Medical Systems (NYSE:INSP) and raises the price target from $335 to $360.

Portfolio Pulse from Benzinga Newsdesk

May 18, 2023 | 1:13 pm